|Bid||24.41 x 800|
|Ask||26.00 x 1100|
|Day's Range||24.29 - 24.67|
|52 Week Range||16.61 - 29.18|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.94|
PIOMBINO DESE (PD), Italy, October 04, 2021--Stevanato Group (NYSE:STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it will begin construction on its new U.S. facility in Fishers, Indiana, this month. The site, expected to be operational in 2023, is expected to enable Stevanato Group to be in closer proximity to its North America pharmaceutical customers and to provide an a
Italian vaccine vials maker Stevanato Group will use funds raised from its recent listing on the New York Stock Exchange to increase production capacity and for selected acquisitions, its executive chairman told Reuters on Thursday. According to its own estimates, it provides vials to about 90% of currently marketed COVID-19 vaccine programs. The medical packaging company raised $453.5 million in its July IPO and aims to build two new plants, which will focus on its high-margin products, including a drug containment solution called EZ-Fill.
PIOMBINO DESE, Italy, August 19, 2021--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance.